OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Pishvaian on Implications of Entrectinib Study in Pancreatic Cancer

March 9th 2018

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the implications of a study of entrectinib in patients with metastatic pancreatic cancer.

Dr. Klopp on the Future of Chemoradiation in Endometrial Cancer

March 9th 2018

Ann H. Klopp, MD, PhD, an associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, discusses the future of chemotherapy in combination with radiation for the treatment of patients with endometrial cancer.

Dr. Wolf Discusses Treatment Options for Multiple Myeloma

March 9th 2018

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses treatment options for patients with multiple myeloma.

Dr. Brentjens Discusses the Goal of Armored CAR T Cells

March 9th 2018

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the goal of armored chimeric antigen receptor (CAR) T cells.

Dr. Al-Niaimi Discusses Cytoreductive Surgery in Ovarian Cancer

March 9th 2018

Ahmed N. Al-Niaimi, MD, assistant professor of obstetrics and gynecology, University of Wisconsin School of Medicine and Public Health, discusses cytoreductive surgery in ovarian cancer.

Dr. Weiss on the Design of the PACIFIC Trial

March 9th 2018

Jared Weiss, MD, associate professor, School of Medicine, UNC Chapel Hill, UNC Lineberger Comprehensive Cancer Center, discusses the clinical applications of the phase III PACIFIC trial in non–small cell lung cancer in the United States.

Dr. Schwartzberg on Emerging Biomarkers in NSCLC

March 8th 2018

Lee S. Schwartzberg, MD, FACP, chief and professor, Division of Hematology/Oncology, the University of Tennessee Health Science Center, medical director, West Clinic, executive director, West Cancer Center, discusses several emerging biomarkers in non–small cell lung cancer (NSCLC).

Dr. Spigel on the Rationale Behind the PACIFIC Trial

March 8th 2018

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the rationale behind the design of PACIFIC, a trial that investigated the use of durvalumab (Imfinzi) in patients with locally advanced, unresectable stage III lung cancer.

Dr. Laramore on Genetic Testing in Hematologic Cancers

March 8th 2018

Andrew Laramore, MD, Anatomic and Clinical Pathology, Diagnostic Pathology Services, discusses some of the known genes that are tested for in hematologic malignancies.

Dr. Castle on Staging Modalities for Men With High-Risk Prostate Cancer

March 8th 2018

Erik P. Castle, MD, professor of urology, Mayo Clinic, discusses traditional imaging modalities and newer counterparts that are used to detect prostate cancer.

Dr. Schuster on Long-Term Outcomes of Lenalidomide and Rituximab in MCL

March 8th 2018

Stephen J. Schuster, MD, professor of hematology/oncology at the University of Pennsylvania Abramson Cancer Center, discusses long-term outcomes of lenalidomide (Revlimid) and rituximab (Rituxan) in mantle cell lymphoma (MCL).

Dr. Sandler Discusses Hypofractionation in Prostate Cancer

March 8th 2018

Howard M. Sandler, MD, chair, Department of Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, director, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses hypofractionation in prostate cancer.

Dr. Venook Discusses Adjuvant Chemotherapy Duration in CRC

March 7th 2018

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses adjuvant chemotherapy duration in colon cancer.

Dr. Kim Discusses Cytoreductive Nephrectomy in Metastatic RCC

March 7th 2018

Hyung L. Kim, MD, Medallion Group Chair in Urology, co-medical director of the Urologic Oncology Center, associate director, Surgical Research in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses cytoreductive nephrectomy in patients with metastatic renal cell carcinoma.

Dr. Blackwell Discusses the HER2CLIMB Study in HER2+ Breast Cancer

March 7th 2018

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the HER2CLIMB study in patients with HER2-positive breast cancer.

Dr. Weber on the FDA Approval for Fixed-Dose of Nivolumab

March 6th 2018

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, 2016 Giant of Cancer Care

Dr. Byrd on Combination Strategies in CLL

March 5th 2018

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the role of combinations in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Kambhampati Discusses the Current Landscape of MDS

March 5th 2018

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the current landscape of myelodysplastic syndromes (MDS).

Dr. Postow Discusses Side Effects with Combinations in Melanoma

March 5th 2018

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses side effects with combination therapy in melanoma.

Dr. Balmanoukian on Immunotherapy Advancements in GU Cancers

March 5th 2018

Ani Balmanoukian, MD, director of Thoracic Oncology, associate director of the Phase I Immune-Oncology Program, The Angeles Clinic and Research Institute, discusses immunotherapy advancements in genitourinary cancers.